The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Graduate Program in Biomedical Sciences, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Adv Cancer Res. 2018;137:115-170. doi: 10.1016/bs.acr.2017.11.003. Epub 2017 Dec 7.
Effective and safe delivery of anticancer agents is among the major challenges in cancer therapy. The majority of anticancer agents are toxic to normal cells, have poor bioavailability, and lack in vivo stability. Recent advancements in nanotechnology provide safe and efficient drug delivery systems for successful delivery of anticancer agents via nanoparticles. The physicochemical and functional properties of the nanoparticle vary for each of these anticancer agents, including chemotherapeutics, nucleic acid-based therapeutics, small molecule inhibitors, and photodynamic agents. The characteristics of the anticancer agents influence the design and development of nanoparticle carriers. This review focuses on strategies of nanoparticle-based drug delivery for various anticancer agents. Recent advancements in the field are also highlighted, with suitable examples from our own research efforts and from the literature.
有效的抗癌药物输送是癌症治疗的主要挑战之一。大多数抗癌药物对正常细胞有毒性,生物利用度差,体内稳定性差。纳米技术的最新进展为成功通过纳米颗粒输送抗癌药物提供了安全有效的药物输送系统。这些抗癌药物的理化和功能特性各不相同,包括化疗药物、核酸治疗药物、小分子抑制剂和光动力剂。抗癌药物的特性影响纳米载体的设计和开发。本文综述了基于纳米粒子的各种抗癌药物的药物输送策略。还强调了该领域的最新进展,并结合我们自己的研究工作和文献中的适当示例进行了说明。
Adv Cancer Res. 2017-12-7
Nanomedicine (Lond). 2017-1
Recent Pat Anticancer Drug Discov. 2019
Biomed Res Int. 2014
Nanomedicine (Lond). 2017-5
Trends Pharmacol Sci. 2014-10-16
Nanomedicine. 2016-2
Biomater Sci. 2015-7
Int J Nanomedicine. 2021
Drug Des Devel Ther. 2025-7-18
Int J Nanomedicine. 2025-6-16
J Nanobiotechnology. 2025-6-13
Nanoscale Adv. 2025-4-16
Explor Target Antitumor Ther. 2025-1-3
Cancer Immunol Immunother. 2025-2-25
Clin Transl Oncol. 2025-2-22
PLoS One. 2017-6-21
Biomacromolecules. 2017-7-10
J Drug Target. 2017-6-18
Mater Sci Eng C Mater Biol Appl. 2017-9-1
Mater Sci Eng C Mater Biol Appl. 2017-9-1